**Table S3.** Univariate analyses of factors that influenced Lenvatinib conversion therapy.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **Category** | **No. of Patients (%)** | | **Univariate** |
| **LEN**  **Conversion +** | **LEN**  **Conversion**  **-** | **p-value** | |
| Age, (years) | ≥75  <75 | 5 (83)  1 (17) | 77 (62)  48 (38) | 0.66 | |
| Sex | Male  Female | 4 (67)  2 (33) | 96 (77)  29 (23) | 0.63 | |
| Etiology | Viral  No-viral | 1 (17)  5 (83) | 69 (55)  56 (45) | 0.10 | |
| ECOG PS | 1  0 | 2 (33)  4 (67) | 47 (38)  78 (62) | 1 | |
| mALBI Grade 1+2a | Yes  No | 5 (83)  1 (17) | 81 (65)  44 (35) | 0.66 | |
| Child-Pugh score 5 | Yes  No | 2 (33)  4 (67) | 59 (47)  66 (53) | 0.69 | |
| BCLC stage | B  C | 5 (83)  1 (17) | 67 (54)  58 (46) | 0.03 | |
| AFP level (ng/mL) | ≥400  <400 | 2 (33)  4 (67) | 42 (34)  83 (66) | 1 | |
| Treatment line | First line | 6 (100) | 80 (64) | 0.09 | |
|  | Later line | 0 (0) | 45 (36) |  | |